The In Silico Discovery of Cefoperazone as a Novel MMP-2 Inhibitor for Ovarian Cancer Therapy
Cefoperazone as MMP-2 Inhibitor for Ovarian Cancer
Abstract
Abstract Views: 0
In silico drug repurposing has emerged as a promising methodology for the identification of novel therapeutic applications for pre-existing pharmaceuticals. This investigation explores the efficacy of eight selected third-generation cephalosporin antibiotics, as potential inhibitor of matrix metalloproteinase-2 (MMP-2) in ovarian cancer. MMP-2 is recognized for its pivotal role in tumor progression and metastasis, rendering it a compelling target for oncological treatment. We assessed the binding affinity and stability of selected cephalosporins with MMP-2 using molecular docking and molecular dynamics simulations. Our findings indicate that only Cefoperazone demonstrates robust binding interactions (∆G -8.1 Kcal/mol) within the active site of MMP-2, suggesting its viability as an effective inhibitor. Furthermore, MD simulations (duration 10 mins) using normal mode analysis (NMA) revealed that the interactions between MMP-2 and Cefoperazone are exceptionally stable under virtual physiological conditions. The low eigenvalue (1.513588e−04) and B-factor further support the stability of the docked complex. Elastic network model analysis indicates that the docked protein molecule atoms are interconnected by flexible springs, suggesting appropriate molecular motion in the vicinity of the binding site. Consequently, these findings offer novel insights into cefoperazone as a potential candidate for MMP-2 inhibition in the treatment of ovarian cancer. This research also demonstrates the efficacy of in silico methodologies in drug repurposing and paves the way for developing targeted therapeutic strategies in the management of ovarian cancer.
Downloads
References
1. Bucur C, Balescu I, Petrea S, et al. Ovarian cancer prevention and screening–where do we stand today? 2024;11(1):99-105.
2. Liu X, Wang X, Sahidullah M, et al. Asvspoof 2021: Towards spoofed and deepfake speech detection in the wild. 2023;31:2507-2522.
3. Murray NPJO. The role of matrix metalloproteinase-2 in the metastatic cascade: a review. 2024;26(1):27-40.
4. Assidi M, Jafri MA, Abu-Elmagd M, et al. Prognostic value of matrix metalloproteinase 2 protein expression in ovarian cancer is age-and stage-dependent. 2022;43(1):26-35.
5. Jia H, Zhang Q, Liu F, Zhou DJAog, obstetrics. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis. 2017;295(3):689-696.
6. Wolosowicz M, Prokopiuk S, Kaminski TWJIJoMS. The complex role of matrix metalloproteinase-2 (MMP-2) in health and disease. 2024;25(24):13691.
7. Cavalcante BRR, Freitas RD, Siquara da Rocha LdO, et al. In silico approaches for drug repurposing in oncology: a scoping review. 2024;15:1400029.
8. Sahu R, Rawal RKJPP. Modulation of the c-JNK/p38-MAPK signaling pathway: Investigating the therapeutic potential of natural products in hypertension. 2024;4(2):100564.
9. Jin G, Wong STJDdt. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. 2014;19(5):637-644.
10. Arda AG, Syaifie PH, Ramadhan D, et al. Activity of propolis compounds as potential MMP1 and MMP2 inhibitors by in silico studies in wound healing application. 2024;12
11. Xia D, Yang X, Liu W, et al. Over-expression of CHAF1A in Epithelial Ovarian Cancer can promote cell proliferation and inhibit cell apoptosis. 2017;486(1):191-197.
12. Saeidnia S. New approaches to natural anticancer drugs. 2015.
13. He X, Yao Q, Fan D, et al. Combination of cefotaxime and cisplatin specifically and selectively enhances anticancer efficacy in nasopharyngeal carcinoma. 2023;23(7):572-584.
14. Ali ZA, Jawad ZNJJoPMS. Anti-Cancer Effect of Cephalexin Loaded on Nano chitosan Against Humane Liver Cancer. 2024;13:15-17.
15. Varghese D, Sunny D, Kurian A, Cherian T, Varghese LJJoAPS. An in silico study on reproposing eravacycline as an MMP inhibitor. 2023;13(1):232-240.
16. Wu S, Fei H, Qu L, Ji W, Chua T-S. Next-gpt: Any-to-any multimodal llm. 2024:
17. Lee KN, Park KH, Ahn K, Im EM, Oh E, Cho IJAJoRI. Extracellular matrix‐related and serine protease proteins in the amniotic fluid of women with early preterm labor: Association with spontaneous preterm birth, intra‐amniotic inflammation, and microbial invasion of the amniotic cavity. 2023;90(1):e13736.
18. Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook. Springer; 2005:571-607.
19. An I. 3DSIG 2010: The 6th Structural Bioinformatics and Computational Biophysics Meeting. 2010;
20. Trott O, Olson AJEOM. Software news and update AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function. 2009;31:455-461.
21. López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón PJNar. iMODS: internal coordinates normal mode analysis server. 2014;42(W1):W271-W276.
22. Gunasena P, Hapuarachchi T, Gunathilake S. Therapeutic uses and spectrum of cephalosporin generations. ResearchGate. https://www. researchgate. net/publication …; 2024.
23. Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. 2013;5(192):192ra85-192ra85.
24. Labay E, Mauceri HJ, Efimova EV, et al. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. 2016;7(23):33919.
25. Kovacs JA, Chacón P, Abagyan RJPS, Function,, Bioinformatics. Predictions of protein flexibility: first‐order measures. 2004;56(4):661-668.
26. Ghosh P, Bhakta S, Bhattacharya M, et al. A novel multi-epitopic peptide vaccine candidate against Helicobacter pylori: in-silico identification, design, cloning and validation through molecular dynamics. 2021;27(2):1149-1166.
Copyright (c) 2025 Fariha javaid Fariha
This work is licensed under a Creative Commons Attribution 4.0 International License.
